 |
|
|
|
PROCYTE ANNOUNCES PUBLICATION OF PATENT APPLICATION
Redmond, Wash.—April 27, 2004—ProCyte Corporation (OTCBB: PRCY.OB),
a company that
develops and markets skin care and therapeutic products for the
dermatology, cosmetic surgery and spa markets, today announced the
Company’s patent application for “compositions containing peptide copper
complexes and soft tissue fillers and methods related thereto”
originally filed in October 2002, has been published by the U.S. Patent
and Trademark Office. This is the fourth new U.S. patent application
that has been published recently in addition to the foreign filings
related to these applications. The Company has seven additional patent
filings pending with the U.S. Patent and Trademark Office and will
continue to make submissions based on work currently underway. If
approved these applications will greatly expand the patent coverage of ProCyte’s copper peptide technology, although there are no specific
dates available when any of these patents will issue or if they will
issue at all.
“We are continuing
to strengthen our patent portfolios as evidenced by the recent Patent
and Trademark Office activity,” said Jack Clifford, President and CEO.
“We are also leading the way with new products like our Neova®
Therapy Dual Action Lotion that uses nanoencapsulation technology
to combine GHK Copper Peptide Complex® and Retinol. Our GHK Copper
Peptide has shown positive results in clinical studies to promote
angiogenesis, new collagen and elastin formation, all of which are
desired outcomes from soft tissue fillers. We expect to initiate
preliminary studies on various materials later this year. ”
ProCyte will release
its first quarter earnings on Wednesday, May 5th and a conference call
is scheduled for 11:30 am Eastern Daylight Time on May 5th. The dial in
number is 800-261-2045 and the access code is 45983#. A replay of the
call will be available until Sunday, May 9 at 9pm Eastern Daylight Time.
The dial in number is 800-294-1193 and the access code is 135554#.
ProCyte Corporation
develops and markets products based on its patented, clinically proven
Copper Peptide technology for skin health, hair care and wound care. The
Company sells directly to dermatologists, plastic and cosmetic surgeons,
spas. The Company also has licenses with partners in the consumer
markets, including its long-term worldwide license agreement with
Neutrogena®, a Johnson & Johnson company. ProCyte’s products
include Neova® Therapy, VitalCopper™, Simple Solutions®
and AquaSanté®
Skin Care products; Complex Cu3® Post-Procedure
Skin Care; GraftCyte® Hair Transplant Care; and Tricomin®
Advanced Care for Thinning Hair. The Company also has the exclusive
distribution rights for Cutanix Corporation’s Quadrinone®
technology for medical and spa markets in the U.S., Canada and Puerto
Rico. Additional information is available by visiting the Company’s
website at www.procyte.com.
###
This release may contain forward-looking statements relating to the
research, development, commercialization, production, marketing and
distribution of the Company's products and future operating results,
which are subject to certain risks and uncertainties that could cause
actual results to differ materially from those projected.
The words “believe,”
“expect,” “intend,” “anticipate,” variations of such words, and similar
expressions identify forward-looking
statements, but their absence does not mean that the statement is not
forward-looking. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties and
assumptions that are difficult to predict. Factors that could affect the
Company’s actual results include its ability to develop, commercialize
and produce new products; the market acceptance of existing and
potential future products; the availability, cost and timely delivery of
materials and services from and performance of third-party suppliers,
manufacturers, distributors, licensees and other collaborative partners;
the satisfaction of regulatory requirements, and the receipt, timing,
terms and conditions of required regulatory approvals. Reference is
made to the Company’s Annual Report on Form 10-K for the year ended
December 31, 2003 filed with the Securities and Exchange Commission for
a more detailed description of such factors. Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak
only as of the date of this release. The Company undertakes no
obligation to publicly update any forward-looking statement to reflect
new information, events or circumstances after the date of this release
or to reflect the occurrence of unanticipated events. |
|
|
|
